Argatroban

Source: Wikipedia, the free encyclopedia.
Argatroban
Clinical data
AHFS/Drugs.comMonograph
License data
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability100% (intravenous)
Protein binding54%
Metabolismhepatic
Elimination half-life39 and 51 minutes
Identifiers
  • (2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-
    [[(3R)-3-methyl-1,2,3,4-tetrahydroquinolin-8-yl]
    sulfonylamino]pentanoyl]-4-methyl-piperidine-2-
    carboxylic acid
JSmol)
  • O=C(O)[C@@H]3N(C(=O)C(NS(=O)(=O)c1cccc2c1NCC(C2)C)CCC/N=C(\N)N)CC[C@@H](C)C3
  • InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15?,17+,18-/m1/s1 ☒N
  • Key:KXNPVXPOPUZYGB-IOVMHBDKSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.[2] In 2000, argatroban was licensed by the Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in patients who have HIT or are at risk for developing it. In 2012, it was approved by the MHRA in the UK for anticoagulation in patients with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.[3]

Argatroban is given intravenously and drug plasma concentrations reach steady state in 1–3 hours.[4] Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Because of its hepatic metabolism, it may be used in patients with renal dysfunction. (This is in contrast to lepirudin, a direct thrombin inhibitor that is primarily renally cleared).

Transitioning to warfarin in individuals with heparin-induced thrombocytopenia

Argatroban is used as an anticoagulant in individuals with thrombosis and heparin-induced thrombocytopenia. Often these individuals require long-term anticoagulation. If

INR caused by argatroban. The combination of argatroban and warfarin may raise the INR to greater than 5.0 without a significant increased risk of bleeding complications.[5]
One solution to this problem is to measure the chromogenic factor X level. A level < 40–45% typically indicates that the INR will be therapeutic (2–3) when the argatroban is discontinued.

References

  1. ^ "Argatroban injection, solution". DailyMed. Retrieved 10 June 2021.
  2. PMID 16148288
    .
  3. ^ "UK launch for Mitsubishi's blood thinner Exembol". 3 July 2012.
  4. PMID 19655821
    .
  5. PMID 16015413
    .

External links

  • "Argatroban". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Argatroban&oldid=1168624618"